GSK secures USD 750 million cancer rights. Goldman keeps GBp 1,860 target for GSK stock

Published on 10/09/2026 at 11:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit GBP 8.41 billion, while net profit fell to GBP 435 million. GSK stock costs EUR 20.84 on October 9, 2026 after EUR 20.76.

Key points in brief

GSK agreed on September 15, 2026, to acquire global rights to a Chimagen cancer program for up to USD 750 million.
Goldman Sachs maintained a Hold rating and a GBp 1,860.00 price target on October 5, 2026.
Second-quarter 2026 revenue reached GBP 8.41 billion, while net profit was GBP 435.00 million.
GSK stock was trading at EUR 20.84 at Lang & Schwarz on October 9, 2026, up 0.39 percent versus the prior close.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK agreed on September 15, 2026, to acquire full global rights to a Chimagen Biosciences trispecific T-cell engager for multiple myeloma in a deal worth up to USD 750 million. According to Markets Insider on October 5, 2026, Goldman Sachs maintained a Hold rating and a GBp 1,860.00 price target for GSK stock.

GSK builds its oncology pipeline

Ground News reported that the Chimagen program is expected to enter Phase I trials in 2027, with milestone payments making up part of the potential USD 750 million value. The asset is designed to bind T cells and two tumor-associated antigens in multiple myeloma.

GSK's latest reported quarter also shows the financial scale behind the pipeline push. Markets Insider said second-quarter 2026 revenue was GBP 8.41 billion, up from GBP 7.99 billion a year earlier, while net profit was GBP 435.00 million versus GBP 1.44 billion.

What does the pipeline spending change?

The September 15 deal adds an early-stage asset rather than near-term revenue, so its value depends on clinical execution after the planned 2027 Phase I start. GSK also reported a measurable clinical comparison on September 13: according to GSK, Ris-Rez reduced the risk of death by 54.00 percent versus topotecan, with median overall survival of 18.50 months versus 10.30 months.

Three dated events shape the story

On September 13, 2026, GSK reported the 54.00 percent reduction in death risk for Ris-Rez. On September 15, 2026, it agreed the USD 750 million Chimagen transaction.

On October 8, 2026, GSK announced a shingles education campaign with Viola Davis for adults aged 50 and older. The next scheduled reporting date is October 28, 2026, for third-quarter results, according to Simply Wall St.

GSK stock trades at EUR 20.84

GSK stock was trading at EUR 20.84 at Lang & Schwarz on October 9, 2026 at 11:43 a.m. CEST, up 0.39 percent versus the prior close of EUR 20.76 on October 8, 2026. The London Stock Exchange is the primary listing venue, and the company trades under ticker GSK.L, according to TradingView.

The further course of trading is shown by the continuously updated real-time quote of GSK stock.